PCM
AMRX icon

Prelude Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Prelude Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,210
Closed -$177K – 1234
2026
Q1 		$177K Buy
+14,210
New +$191K 0.01% 940
2025
Q4 		– Sell
-13,801
Closed -$138K – 1281
2025
Q3 		$138K Sell
13,801
-24,322
-64% -$218K 0.01% 1014
2025
Q2 		$308K Buy
38,123
+25,030
+191% +$189K 0.03% 601
2025
Q1 		$110K Buy
13,093
+2,349
+22% +$19.6K 0.01% 1028
2024
Q4 		$85.1K Buy
+10,744
New +$90.1K 0.01% 1108
2024
Q2 		– Sell
-10,841
Closed -$65.7K – 1202
2024
Q1 		$65.7K Buy
+10,841
New +$61.1K ﹤0.01% 1236
2023
Q1 		– Sell
-12,562
Closed -$25K – 1161
2022
Q4 		$25K Buy
+12,562
New +$28.2K ﹤0.01% 1169
2021
Q1 		– Sell
-338,426
Closed -$1.55M – 1513
2020
Q4 		$1.55M Buy
338,426
+64,454
+24% +$286K 0.04% 363
2020
Q3 		$1.06M Buy
273,972
+132,130
+93% +$565K 0.05% 267
2020
Q2 		$675K Sell
141,842
-75,000
-35% -$309K 0.04% 403
2020
Q1 		$755K Buy
+216,842
New +$918K 0.05% 255
2019
Q3 		– Sell
-1,300
Closed -$9K – 1689
2019
Q2 		$9K Buy
+1,300
New +$13.3K ﹤0.01% 1414
2018
Q3 		– Sell
-1,341
Closed -$22K – 1709
2018
Q2 		$22K Buy
+1,341
New +$23.5K ﹤0.01% 1331

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Prelude Capital Management's AMRX Position: Q2 2026 in Review

Prelude Capital Management sold out of Amneal Pharmaceuticals (AMRX) in Q2 2026, closing a stake of 14,210 shares — an estimated $177K sold.

Prelude Capital Management first reported a position in AMRX in Q2 2018 and held it in 13 quarters. The position peaked at $1.55M in Q4 2020. 310 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Prelude Capital Management reported no remaining Amneal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 14,210 Amneal Pharmaceuticals shares in Q2 2026, an estimated $177K.
  • Prelude Capital Management first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 13 quarters.
  • Prelude Capital Management's Amneal Pharmaceuticals position peaked at $1.55M in Q4 2020.
  • 310 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.